Leading provider of healthcare products for women Hologic Inc. (HOLX - Free Report) is scheduled to exhibit some of its newest offerings at the annual meeting of the European Society of Radiology, during Mar 7-11, in Vienna, Austria. This offers an ideal platform for the company to showcase its most recent products at the largest radiological meeting in Europe – the European Congress of Radiology (ECR).
Hologic will display its extensive suite of healthcare solutions for the screening and diagnosis of breast cancer, breast biopsy, osteoporosis risk assessment, medical MRI coils and extremity imaging. Management is enthusiastic about its breast tomosynthesis program including the introduction of a tomosynthesis biopsy option for the company’s Affirm breast biopsy guidance system. Hologic will also conduct education sessions and training workshops for tomosynthesis-guided breast biopsy.
The company received the European CE Mark for its Selenia Dimensions breast tomosynthesis system in 2008 following the U.S. Food and Drug Administration approval in 2011. Apart from Selenia system and the most recent innovation for the 3D technology platform – a tomosynthesis biopsy option for the 'Affirm breast biopsy guidance system', Hologic will also present its latest version of C-View software. These offerings are expected to improve standards of patient care and workflow efficiencies.
Moreover, Hologic is set to display two new products at ECR, namely Selenia Dimensions Avia Package and Flouroscan InSight-FD Mini C-arm. While the Avia Package provides cost effective 2D screening and diagnostic solutions, the Mini C-arm will meet the needs of orthopedic and extremity surgeons by improving workspace access and ease of positioning.
Given that ECR hosts more than 20,000 participants representing the medical specialty of radiology across Europe and the Mediterranean, the exhibition presents a unique opportunity to create brand awareness for Hologic and thereby promote its innovative products.
The coherent focus on Selenia is encouraging following the ongoing shift from Hologic’s legacy Selenia product lines. According to the company, its breast tomosynthesis technology is ‘game-changing’. Notably, expectations from the technology are sky-high. However, over the past few quarters, Hologic witnessed several challenges in the form of economic uncertainties in Europe, slower sales cycles and increasing pricing pressure.
In the light of these facts, the estimates for the ongoing fiscal have remained stagnant over the last 90 days. Accordingly, the stock carries a Zacks Rank #3 (Hold). While we remain on the sidelines for Hologic, other medical stocks such as Cyberonics , Given Imaging and Medical Action , each carrying a Zacks Rank #1 (Strong Buy) are expected to do well.